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Secreted proteins including cytokines, chemokines, and growth factors represent
important functional regulators mediating a range of cellular behavior and cell–cell
paracrine/autocrine signaling, e.g., in the immunological system (Rothenberg, 2007),
tumor microenvironment (Hanahan and Weinberg, 2011), or stem cell niche (Gnecchi
et al., 2008). Detection of these proteins is of great value not only in basic cell biology
but also for diagnosis and therapeutic monitoring of human diseases such as cancer.
However, due to co-production of multiple effector proteins from a single cell, referred to
as polyfunctionality , it is biologically informative to measure a panel of secreted proteins,
or secretomic signature, at the level of single cells. Recent evidence further indicates that
a genetically identical cell population can give rise to diverse phenotypic differences (Niepel
et al., 2009). Non-genetic heterogeneity is also emerging as a potential barrier to accurate
monitoring of cellular immunity and effective pharmacological therapies (Cohen et al., 2008;
Gascoigne and Taylor, 2008), but can hardly assessed using conventional approaches that
do not examine cellular phenotype at the functional level. It is known that cytokines, for
example, in the immune system deﬁne the effector functions and lineage differentiation
of immune cells. In this article, we hypothesize that protein secretion proﬁle may
represent a universal measure to identify the deﬁnitive correlate in the larger context of
cellular functions to dissect cellular heterogeneity and evolutionary lineage relationship in
human cancer.
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THE SECRETOMIC PROFILE OF SINGLE T CELLS DEFINES A
CORRELATE TO PROTECTIVE IMMUNE RESPONSES
To establish our hypothesis and elucidate the strategies, we would
like to start with the important discoveries in the ﬁeld of immunol-
ogy that have enhanced our understanding of protective immune
responses elicited by T cells in response to infection and vac-
cination. T cells demonstrate diverse and important functional
activities in mediating immune response that provide protec-
tion against various infections (Precopio et al., 2007; Sallusto and
Lanzavecchia, 2009; Bhatia et al., 2012). Upon encountering spe-
ciﬁc pathogenic antigens that generates polarizing stimulus that
induces development of speciﬁc phenotype, immune cells are
activated and proliferate. After their activation, immune cells
differentiated into highly heterogeneous functional lineages and
attain a wide variety of effector functions (O’Garra, 1998; Dar-
rah et al., 2007; Precopio et al., 2007; Betts et al., 2006; O’Shea
et al., 2008; Seder et al., 2008; Zhu and Paul, 2010; Ma et al., 2011).
Effector T cells can regulate and prime their effector mechanisms
to clear the infection by producing and secreting diverse cytokines,
which play important roles in orchestrating immune responses
and controlling pathogenic conditions (Wong and Goeddel, 1986;
Harty et al., 2000; Sandberg et al., 2001). T cells develop into highly
heterogeneous subpopulations,which canbe classiﬁedby their dif-
ferentiation states based on surface marker phenotypes and then
by diverse functional proﬁles (Figure 1), as reﬂected by distinct
cytokine production patterns (Sandberg et al., 2001; Appay et al.,
2008; Seder et al., 2008; Ma et al., 2011; Han et al., 2012).
The critical issues in developing effective vaccines have been
comprehensive characterization of these complex T cell responses
(O’Garra, 1998; Darrah et al., 2007; Seder et al., 2008). It is impor-
tant to identify the correlation of both quality and magnitude
of T cell immunity with the protective responses generated fol-
lowing infection or vaccination (De Rosa et al., 2004). Due to
increasing phenotypic and functional heterogeneity of effector T
cells and the plasticity of T cell differentiation, there have not
been clearly deﬁned correlates of immune protection against spe-
ciﬁc pathogens. Correlate of immune protection is a measurable
predictor of an individual’s immunity to a pathogen following
infection or vaccination (Zhu and Paul, 2010). Deﬁning correlates
of protective T cell immunity has been particularly challenging for
immunologists because the degrees of protection does not clearly
match with any known T cell phenotypes (O’Shea et al., 2008).
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FIGURE 1 | Protein secretion profile defines phenotype and stage
of CD4+ T cell differentiation. It is known that human naïve CD4+
T cells differentiate through multiple stages including central memory
and effector memory T cells to become terminally differentiated effector
T cells that are monofunctional (IFNg+), less immunoprotective, and
approaching the commitment to apoptosis. The triple positive polyfunctional
T cells were found more potent and durable to generate effective immune
protection over a prolonged time. Due to the limitation of single-cell
cytokine proﬁling technology, it remains unclear how many effector
functions are associated with single T cells. The general trend is
polyfunctionality positively correlates to the effectiveness of T cell responses
against infection or tissue dysfunction. There is also a diverse range of
functional phenotypes deﬁned by distinct cytokine proﬁles during the process
ofT cell activation and differentiation. The entire repertoire of heterogeneousT
cells collectively deﬁnes the quality and protection of T cell-mediated
immunity.
Quantiﬁcation and characterization of these complex and het-
erogeneous T cell responses have become critical to understand
disease pathogenesis and develop preventive or therapeutic vac-
cines that elicit potent, durable, and speciﬁc immune responses
(Precopio et al., 2007; Betts et al., 2006; Zhu and Paul, 2010).
The functional proﬁles of TH1 cells (type I helper T cells), one
of major functional subsets differentiated from naïve CD4 T cells,
demonstrated marked heterogeneity (O’Garra, 1998; Sandberg
et al., 2001). Functional analysis of effector T cells using multi-
parameter ﬂow cytometry could delineate a number of distinct
functional subsets that produce and release different combina-
tions of cytokines within immune response elicited by bacterial
infection (De Rosa et al., 2001; Perfetto et al., 2004). The study by
De Rosa et al. (2004) measured and characterized the secretion
proﬁles of ﬁve cytokines at the single-cell levels using multi-
parameter ﬂow cytometry, and discovered that the activated T
cells express diverse cytokine proﬁles. Speciﬁc subsets with the
ability to produce and secrete multiple cytokines simultaneously
conferred more effective and durable protection and other effector
functions than the subsets that secreted single cytokines (O’Garra,
1998; Darrah et al., 2007; Appay et al., 2008; Betts et al., 2006;
Seder et al., 2008; Han et al., 2012). Frequency of polyfunctional T
cells that secreted three distinct cytokines simultaneously and the
quality of cytokine secretion best correlated to the degree of pro-
tection (De Rosa et al., 2001; Campbell and Polyak, 2007; Polyak,
2011; Marusyk et al., 2012). The induction and maintenance of
polyfunctional CD8+ T lymphocytes that produce 5+ cytokines
contributes to effective anti-viral immune protection (O’Garra,
1998). The immune responses elicited by vaccination that gener-
ated optimal protection and resulted in a low level of pathogenic
antigens are dominated by multifunctional T cells (Precopio et al.,
2007; Zhu andPaul,2010). Recently amicrochip technology allows
for simultaneous measurement of up to 12 cytokines to function-
ally proﬁle antigen-speciﬁc CTL (cytotoxic T lymphocytes), which
are the main effectors targeting intracellular pathogens (Wong
and Goeddel, 1986; Seder et al., 2008; Attig et al., 2009). This
device has enabled the detection and characterization of poly-
functional heterogeneity within a phenotypically homogeneous T
cell population at single-cell levels. Haining (2012) and Han et al.
(2012) used serial microengraving method to design an array of
nanowells in which single T cells are isolated and stimulated to
cytokine secretion, and characterized the dynamic evolution of
cytokine secretion by individual T cells. Recent single immune
cell studies also suggest that the ability of effector immune cells to
secrete multiple cytokines simultaneously, named polyfunction-
ality, correlates with protective immune responses (Darrah et al.,
2007; Precopio et al., 2007; Betts et al., 2006; O’Shea et al., 2008;
Seder et al., 2008; Zhu and Paul, 2010; Ma et al., 2011).
CELLULAR HETEROGENEITY IN HUMAN CANCER
Almost all solid and metastatic tumors display startling pheno-
typic and morphologic heterogeneity between and within tumors
as well as among different cancer-afﬂicted individuals (Campbell
and Polyak, 2007; Polyak, 2011). Tumor is comprised of highly
heterogeneous subpopulation of cells that frequently exhibit
substantial variability in virtually all discernible phenotypic fea-
tures, especially the traits associated with tumorigenesis such
as self-renewal capacity, proliferative, invasive, and metastatic
potential (Heppner and Miller, 1983; Heppner, 1984; Marusyk
and Polyak, 2009; Denysenko et al., 2010; Polyak, 2011; Marusyk
et al., 2012). Tumors are not rigid and terminally differentiated
cell mixtures, but dynamic organisms which continuously change
their properties to adapt to hostile surroundings (Gatenby and
Gillies, 2008).
The basic mechanisms by which tumor heterogeneity is evolved
and regulated have not been clearly understood and the subject
of much discussion (Tu et al., 2002; Michor and Polyak, 2010).
Recently, there have been two ideas proposed to elucidate the
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establishment of tumor heterogeneity (Hanahan and Weinberg,
2011). First, the concept of cancer stem cells (CSCs) postulates that
only a small population of cells, or “cancer stem cells,” are respon-
sible for growth, maintenance, and progression of tumors (Reya
et al., 2001; Bjerkvig et al., 2005; Ichim and Wells, 2006; Marusyk
and Polyak, 2009; Michor and Polyak, 2010). Second, there is the
clonal evolution model. The model states that tumor progression
is driven as cancer cells over time accumulate highly diverse com-
binations of genetic and epigenetic alterations (Maley et al., 2006;
Marusyk and Polyak, 2009; Sottoriva et al., 2010; Polyak, 2011;
Ding et al., 2012). To design an effective and robust personalized
therapy that prevents tumor relapse, it is essential to understand
the causes and mechanisms of tumor heterogeneity.
Tumor heterogeneity also signiﬁcantly complicates and
impedes investigation and clinical diagnostics of cancer. Because
tumor subpopulations exhibit substantial variability in sensitiv-
ities to various therapeutic interventions such as chemotherapy,
radiation therapy, and immunotherapy, designing effective can-
cer therapies has posed a major challenge (Håkansson and Tropé,
1974; Hill et al., 1979; Olsson and Ebbesen, 1979; Heppner and
Miller, 1983; Schilsky, 1987). One of the major reasons for failure
of current cancer therapies is relapse or tumor recurrence after
initial remission. Although most cancer cells initially respond to
treatment that attempt to selectively kill dividing tumor cells, can-
cer therapy often fails because there is a small population of cells
that re-establish the tumor (Marusyk et al., 2012). Those cells often
exhibit potent tumor-initiating capabilities, have intrinsic resis-
tance to treatment, or acquire the mutations that reduce efﬁcacy
of treatments (Roche-Lestienne et al., 2003; Mullighan et al., 2008;
Ding et al., 2012; Marusyk et al., 2012). In order to stratify patients
and predict the therapeutic response, it is required to identify the
correlates that can deﬁne tumor cell heterogeneity, differentia-
tion stage, lineage relationship, and interactions within a complex
microenvironment in the clinical settings.
SECRETOMIC PROFILES OF SINGLE TUMOR CELLS AS A
DEFINITE CORRELATE OF TUMOR HETEROGENEITY AND
EVOLUTION
In this article, we would like to introduce a new strategy that
may help to assess the extent of tumor heterogeneity, eluci-
date the fundamental mechanisms of how tumor heterogeneity
inﬂuence tumor progression and therapeutic responses, and pro-
vide valuable insights for designing effective personalized cancer
treatments. We hypothesize that a single-cell proteomic secretion
proﬁle may be identiﬁed as a deﬁnite correlate to tumor hetero-
geneity and evolution. A major challenge in investigating tumor
heterogeneity and developing effective diagnostic and therapeutic
tools has been the lack of adequate strategies to comprehen-
sively characterize intra-tumor heterogeneity. To fully characterize
genetic and phenotypic heterogeneity exhibited within a tumor,
the new technologies with the ability to analyze almost every
aspect of phenotype at the single-cell level must be developed
(Bhatia et al., 2012). Analyzing secretion proﬁles of soluble medi-
ators such as cytokines and growth factors at single-cell levels
is particularly interesting because secretomic proﬁles of effector
T cells can be used to characterize the magnitude and quality
of T cell responses and predict a degree of immune protection
(Betts et al., 2006; Darrah et al., 2007; Precopio et al., 2007; Seder
et al., 2008). Like diverse mixtures of cells constituting tumors,
effector T cells exhibit substantial functional and phenotypic het-
erogeneity, so the similar strategy will be employed to deﬁne the
extent of tumor heterogeneity and predict tumorigenic poten-
tial and drug-resistance. Our preliminary result also suggests
that the protein secretion proﬁle evolves as tumor stem cells
differentiate.
EMERGING MICROCHIP TECHNOLOGIES TO ANALYZE
SINGLE-CELL PROTEIN SECRETION PROFILES
Deﬁning molecular signatures that indicate the status of human
disease or the protective immune response following interventions
like vaccines has become one of the central goals in molec-
ular medicine. Characterizing protein secretomic signatures at
the single-cell resolution would improve studies of the roles of
cellular heterogeneity in pathogenesis, responses to drugs, and
cell differentiation (Tay et al., 2010; Agasti et al., 2012). Several
new technologies that enabled quantitative single-cell proteomic
analysis and characterization of functional andphenotypic hetero-
geneity shown by diverse cell types have recently been introduced
(Fan et al., 2008; Han et al., 2011, 2012; Ma et al., 2011). Many ana-
lytical tools have been developed using a wide range of materials
and techniques to achieve more efﬁcient isolation of single cells,
and multiplexed detection and characterization of secreted pro-
teins (Chin et al., 2004; Rettig and Folch, 2005; Love et al., 2006;
Zhu et al., 2009; Han et al., 2011). Recent efforts have reported
the development of a novel integrated microﬂuidic barcode chip
platform that enables the rapid, high-content, and multiplexed
detection and quantitative assessment of various biomarkers of
single cells (Fan et al., 2008; Ma et al., 2011). The integrated blood
barcode chip (IBBC) enabled the multiplexed and rapid measure-
ment and quantiﬁcation of a panel of plasma proteins, including
the low abundance cytokines, chemokines implicated in tumor–
immune interaction, from a ﬁnger prick of human blood (Fan
et al., 2008). By integrating microﬂuidic hydrodynamic principles,
the platform enables rapid and effective on-chip blood separation.
It employed DNA-encoded antibody library (DEAL) technique,
which involves DNA-directed immobilization of antibodies, to
create antibody barcode array for in situ measurement of plasma
proteins (Fan et al., 2008). The single-cell barcode chip (SCBC)
has been developed to enable comprehensive characterization of
the functional and phenotypic heterogeneity of single immune
cells (Ma et al., 2011). The SCBC module consists of a microﬂu-
idic system comprised of two polydimethylsiloxane (PDMS) layers
and the microscopic slide coated with antibodies (high-density
antibody barcode array). The platform has demonstrated multi-
plexed measurement of a large number of proteins at a single-cell
level, and on-chip, rapid, and high-content assessment of protein
secretion patterns (Ma et al., 2011). Its capability was validated by
detecting multiple cytokine secretions from single macrophages
and then polyfunctional proﬁling of tumor antigen-speciﬁc cyto-
toxic T cells from patients being treated by adoptive T cell transfer
therapy (Ma et al., 2011). Varadarajan et al. (2012) reported the
design of integrated single-cell analysis to detect and recover
antigen-speciﬁc CD8+ T cells based on their cytokine secre-
tion proﬁles. Han et al. (2011) introduced an approach based on
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microengraving that permits quantitative measurements of the
rates of cytokine secretion from single immune cells (Olsson and
Ebbesen, 1979; Seder et al., 2008). The design minimizes the total
number of cells to be interrogated by using a nanowell-array that
could retrieve and characterize single CD8+ T cells (Love et al.,
2006; Han et al., 2011; Varadarajan et al., 2012).
To determine and characterize the protein secretomic pro-
ﬁles of single tumor cells, we have developed and optimized a
novel single-cell analysis microchip. This technology will allow
for rapid, high-content (more than 1000 single cells), and highly
multiplexed measurement of single-cell protein secretion (>14
proteins). The module will be comprised of two major compo-
nents: ultra-high-density antibody barcode chip and microﬂuidic
single capture platform. We have successfully fabricated a PDMS
chip consisting of a sub-nanoliter cell capture microchamber
array (unpublished data). The PDMS-based microwell array can
rapidly and efﬁciently capture more than 1000 single cells in a
single chip, and the captured cells can be cultured and monitored
inside the microchambers that provide physiologically relevant
microenvironment. We also aim to employ spectral and spatial
multiplexing to signiﬁcantly increase the number of functional
proteins (up to 45 proteins) and single cells (up to 4000 cells) to be
analyzed.
To make our platform a more versatile research tool and
effective for clinical applications, the high-content and fully auto-
mated imaging scheme to image and analyze an entire chip need
to be developed. We are in a process of creating novel imag-
ing algorithms with the capacity for detection, counting, and
characterization of captured single cells in a rapid and fully
automated manner. In order to comprehensively characterize
the diverse cellular components, especially highly heterogeneous
immune cell compartments, of tumor microenvironment, we
are in a process of developing four-color ﬂuorescence imag-
ing to identify phenotypic surface markers of captured single
cells for rapid identiﬁcation of their diverse phenotypes in con-
junction of single-cell protein secretion proﬁling. Integration of
these two approaches in a single microchip might provide an
effective strategy to deﬁne a correlation between distinct cell phe-
notypes and cytokine secretion, which may lead to improved
understanding of the roles of highly heterogeneous cellular com-
ponents in the tumor microenvironment in promoting tumor
development.
PROTEIN SECRETOMIC PROFILING AS A TOOL TO STUDY THE
CYTOKINE NETWORKS MEDIATING COMPLEX
TUMOR–MICROENVIRONMENT INTERACTION
Although tumor growth is typically initiated when a single cell
acquires genetic abnormalities that confer its proliferative advan-
tages and drive the malignant transformation, tumors do not
develop alone, nor are they mere collections of malignant cells
with unrestricted proliferation rate (Weiner, 2008; Marusyk et al.,
2012; Wu et al., 2012a,b). The decades of research have led to the
view that tumor cells actively interact with the tumor microenvi-
ronment composedof heterogeneous cell types, and their interplay
signiﬁcantly promotes tumor growth, progression, and metastasis,
also drives co-evolution with tumor microenvironment (Mocellin
et al., 2001; Dranoff, 2004; Weiner, 2008; Marusyk et al., 2012;
Wu et al., 2012a,b). The interplay between these cells compris-
ing the tumor microenvironment are orchestrated by the complex
autocrine and paracrine signaling networks, which are mediated
by the sets of small soluble proteins such as cytokines, growth fac-
tors, and chemokines (Irish et al., 2006; Huang et al., 2007; Raman
et al., 2007; Ma et al., 2011). Cytokines are secreted or membrane-
bound protein mediators that are involved in diverse biological
functions (Dranoff, 2004; Elsawa et al., 2011). When produced
in the malignant microenvironment, cytokines and tumor cells
form a comprehensive network that have profound inﬂuences on
tumor growth and progression bymodulating the tumormicroen-
vironment (Dranoff, 2004; Sheu et al., 2008; Elsawa et al., 2011).
The cytokines such as the tumor-necrosis factor (TNF) are pro-
duced by immune cells, and can improve the efﬁcacy of the T
cell priming and induce adaptive anti-tumor immunity (Zou,
2005). On the other hand, certain cytokines have been associ-
ated with poor patient outcomes, and reported to promote tumor
growth and inhibit anti-tumor immune response (Wojtowicz-
Praga,1997;Mocellin et al., 2001; Ramanet al.,2007). For example,
imbalanced production of interleukin 6 (IL-6), vascular endothe-
lial growth factor (VEGF), or macrophage colony-stimulating
factor (M-CSF) inhibit adaptive anti-tumor immunity by sup-
pressing dendritic cell maturation and activating regulatory T
cells (Treg) to aid tumor cells in evading immune-surveillance
(Zou, 2005). Transforming growth factor beta (TGF-β), which
is abundantly expressed in many pathological conditions, heavily
inﬂuence tumor growth and maintenance as the cytokine plays
important roles in forming tumor microenvironment, and facili-
tating angiogenesis (Wojtowicz-Praga, 1997; Zou, 2005; Bierie and
Moses, 2006; Sheu et al., 2008).
Targeting and manipulating the cytokine balance have shown
the therapeutic efﬁcacy in previous trials (Wojtowicz-Praga, 1997;
Zou, 2005; Bierie and Moses, 2006; Sheu et al., 2008; Weidle
et al., 2010; Dinarello, 2011). The elucidation of the composition
and function of cytokine networks in the tumor microenviron-
ment may identify the targets for potent cancer therapy (Dranoff,
2004; Weiner, 2008). But, a systems-level study, which not just
investigates the roles of individual factors, but comprehensively
assesses complex signaling networks and recapitulates the dynam-
ics of tumor microenvironment, has yet to be realized (Wu et al.,
2012a,b). Despite the importance of characterizing the composi-
tion and function of cytokines during tumor development, there
have been only a few studies to characterize the complex interplay
among different cell types and cytokines within the microenviron-
ment (Egeblad et al., 2008; Shi et al., 2012; Wang et al., 2012; Wu
et al., 2012a,b). Shi et al. (2012) developed the SCBC for quanti-
tative and multiplexed assay of intracellular signaling proteins in
single tumor cells. The platformcanprovide a systematic approach
to analyze thenature of perturbed signaling transductionnetworks
in the tumor. Wang et al. (2012) utilized the single-cell microchip
to assess how cell signaling pathways associated with tumorigen-
esis are inﬂuenced by cell–cell interaction at single-cell levels. To
study the tumor microenvironment in vivo, Egeblad et al. (2008)
developed amulticolor imaging technique to analyze the dynamics
and interactions of multiple stromal cell types within the tumor
microenvironment via direct observation. Most recently, Yu and
his colleagues performed in silico stochastic study of glioblastoma
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multiforme (GMB) microenvironment (Wu et al., 2012a,b). Their
model reconstructed the complex cell-to-cell communications in
the tumor microenvironment to assess the effects of cytokine-
mediated signaling pathways in GMB development. Their model
comprises 5 cell types, 15 proteinmediators, and 69 signaling path-
ways, reﬂecting highly heterogeneous tumor microenvironment
(Wu et al., 2012b). This study provides insights into the dynamics
of diverse cell populations comprising the tumor microenviron-
ment and the roles of cytokine signaling in the evolution of tumor
microenvironment. The cytokine network analysis also identi-
ﬁed several key molecules and pathways that play an important
role in tumor development and consequently new therapeutic
strategies can be designed to target cytokines such as IL-2 and
granulocyte-macrophage colony-stimulating factor (GM-CSF), in
tumor microenvironment to treat human cancer (Weiner, 2008;
Marusyk et al., 2012).
We speculate that the analysis of single tumor cell secretion
proﬁles from a novel clinical microchip will lead to a more com-
plete model that predicts the dynamics of tumor evolution and
aids in developing more effective personalized medicine. Each
individual tumor cells display unique protein secretion proﬁles
as they secrete unique combinations of cytokines at differing
kinetics to regulate widely diverse functions during tumor pro-
gression. Signiﬁcant research efforts have been made recently to
develop single-cell proteomics technologies and powerful clinical
tools to examine the heterogeneity of tumor microenvironment
and complex cytokine-mediated signaling networks, and enable
personalized therapy that targets the tumor microenvironment
(Irish et al., 2006; Xu et al., 2006; Huang et al., 2007; Ma et al.,
2011). Our recently developed single-cell analysis microchip will
be employed to experimentally measure the magnitude, quality,
and dynamics of cytokine secretion by the cells comprising tumor
microenvironment. The single-cell cytokine secretion proﬁle of
the tumorwill, for the ﬁrst time, allow reconstruction of a systems-
level and large-scale intercellular cytokine signaling network at
a single-cell resolution. We also propose to develop new multi-
color ﬂuorescence imaging technologies that identify single-cell
phenotypic markers and enable rapid molecular phenotyping. By
integrating the imaging technologies with single-cell proteomics
microchip, we expect to directly assess the behavior of the cells
in tumor microenvironment and study how tumor cell cytokine
secretion correlates to their phenotypic characteristics and interac-
tion with other cells at the single-cell level. We anticipate that this
approach will not only improve cancer diagnosis and stratiﬁcation
but also represents an informative tool to monitor the response of
patients, in particular, the one treated by immunotherapy such
as cytokine therapeutics, antibody therapy (anti-CTLA4 and anti-
PD1), or adoptive T cell therapy that augment the function of
anti-tumor immune response in tumor microenvironment to cue
cancer (Weiner, 2008).
IDENTIFICATION OF CANCER STEM CELLS AND LINEAGE
DIFFERENTIATION – UNDERSTANDING TUMOR EVOLUTION
AND HETEROGENEITY
The CSCs perspective suggests that a small subset of cells with
stem cell properties including indeﬁnite proliferative potential is
responsible for driving tumor initiation and progression (Reya
et al., 2001; Michor and Polyak, 2010). It is one of two major
mechanisms that have been proposed to elucidate the origins of
tumor heterogeneity. CSCs possess the high self-renewal capacity
and unique ability to differentiate, which gives rise to highly het-
erogeneous cell types that constitute the majority of the tumors,
and generates intra-tumor heterogeneity (Hwang-Verslues et al.,
2009; Marusyk and Polyak, 2009; Michor and Polyak, 2010). The
study by Vermeulen et al. (2008) observed that CSCs from human
colon cancer possess multi-lineage differentiation capacity. Recent
studies have observed that stem cells are usually preferential targets
for mutations that accumulate to cause neoplastic transformation
(Bonnet and Dick, 1997; Miyamoto et al., 2000; Betts et al., 2006).
CSCs might explain why majority of conventional therapies fail
due to tumor relapse after initial remission. It has been suggested
that more aggressive cancers that are more likely to relapse con-
tain more CSCs (Al-Hajj et al., 2004; Singh et al., 2004; Bao et al.,
2006; Zhou et al., 2009). Many CSCs are relatively more resistant
to chemotherapy due to their anti-apoptotic pathways and resis-
tance to oxidative or DNA damage (Reya et al., 2001; Li et al., 2006;
Diehn et al., 2009).
However, the deﬁnitive cellular or molecular biomarkers that
identify tumor-initiating cells have not yet determined. The study
by Hwang-Verslues et al. (2009) identiﬁed different subpopula-
tions of cells displaying distinct tumorigenic abilities within the
breast cancer cell line. The discoveries suggest that there are mul-
tiple lineages of CSCs, which can subsequently be differentiated
into more diverse cells. The CSC perspective views the tumors as
hierarchical organization composed of multiple lineages of differ-
entiated cells with distinct phenotypes. The analysis of single-cell
secretomic proﬁles shows that while every single cell exhibits dis-
tinct secretomic proﬁles, there are groups of single cells with
comparable secretomic proﬁles. Based on single-cell secretomic
proﬁles, the entire tumor cell population may be compartmental-
ized into multiple clusters, each of which is a group of cells that
have similar or related cytokine secretion patterns. The multiple
groups of single cells classiﬁed based on the secretion proﬁle may
represent distinct lineages originated from the differentiation and
evolution of CSCs. Our study has shown marked change of pro-
tein secretion proﬁles from human brain tumor cells undergoing
differentiation to mature tumor cells, suggesting the possibility
of using secretomic signatures to deﬁne tumor cell differentiation
and heterogeneity (Figure 2).
The mechanisms by which CSCs acquire their tumorigenic and
metastatic abilities to promote tumor growth, metastasis, and
resistance to therapy have not been fully understood. As nor-
mal stem cells are inﬂuenced by their “niche,” CSCs are regulated
by, and in turn regulate, the extrinsic signals generated within
the tumor microenvironment (Karnoub et al., 2007; Weiner, 2008;
Korkaya et al., 2011). Heterogeneous cell types that constitute the
tumor microenvironment secrete the pro-inﬂammatory cytokines
such as IL-6 or IL-8 that increase tumorigenic potential and pro-
mote therapeutic-resistance (Scheller et al., 2006; Levina et al.,
2008; Liu et al., 2011). In turn, tumorigenic cells also produce
and secrete various factors to enhance their survival and prolif-
eration. Recent studies have found that the capabilities of CSCs
to sustain tumor growth and promote resistance to various ther-
apies are associated with their high ability to produce soluble
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FIGURE 2 | Protein secretion profile correlates to the stage of cancer
stem cell differentiation. (A) Heat map showing the protein secretion
proﬁles measured at different times during the differentiation of human
glioma stem cells in vitro. (B) Schematic depiction of the stage of glioma
stem cell differentiation as identiﬁed by emergence of cytokine secretion.
In our protein assay panel, glioma stem cells appear to be relatively
“quiescent.” During the differentiation process, these cells begin to
produce a number of functional proteins and gradually become the
phenotype of mature tumor cells.
mediating factors such as cytokines and growth factors (Todaro
et al., 2007; Weiner, 2008; Iliopoulos et al., 2009; Tang et al., 2012).
The studydiscovered that the levels of numerous cytokines, growth
factors, and chemokines were two- to threefolds higher in iso-
lated CSC-derived tumors than parental tumor cells (Levina et al.,
2008; Tang et al., 2012). The production of IL-4 by colon CSCs
contributes to higher therapeutic-resistance as IL-4 promotes the
expression of anti-apoptotic genes and upregulates resistance to
apoptosis of CSCs (Todaro et al., 2007; Iliopoulos et al., 2009).
These studies suggest that the greater ability to produce multi-
ple cytokines has been correlated to tumorigenic and metastatic
potential. From the single-cell secretion proﬁles, we can iden-
tify the groups of tumor cells characterized by the signiﬁcant
secretion of multiple, speciﬁc cytokines. These groups may elicit
greater tumorigenic potentials and promote the evolution of more
aggressive and invasive cancer phenotypes. Because our single-
cell analysis microchip allows comprehensive characterization of
phenotypes of captured single cells, including their surface pheno-
types, motility, and viability, we hope to determine the correlation
between speciﬁc cytokine secretion proﬁles of individual cells
and their tumorigenic potentials and differentiation stages. The
cytokine secretion proﬁles of single tumor cells can be used to
characterize a tumor hierarchy and serve as biomarkers for tumor-
initiating cells or different lineages with varying tumorigenicity
and treatment-resistance.
OUTLOOK, CLINICAL APPLICATION, AND UTILITY
The effective targeting of cancerous cells with greater tumori-
genic potential and intrinsic drug-resistance can prevent cancer
relapse or persistent growth, and when combined with conven-
tional therapy that kills the rapidly dividing cells, it can potentially
cure cancer (Vermeulen et al., 2008; Zhou et al., 2009; Chen et al.,
2010; Michor and Polyak, 2010). Our single cell-based cytokine
secretion analysis would provide framework and new insight for
designing effective therapeutic strategies by dissecting hierarchi-
cal organization of tumor microenvironment in hope to identify
the speciﬁc cell subsets with higher tumorigenic and metastatic
potential, and resistance to treatment. Single-cell secretomic pro-
ﬁling could become a new means for quantitative characterization
of the extent of tumor heterogeneity, with which oncologists can
diagnose the stage of cancer and likelihood of development of
metastatic cancer for individual patients, leading to personal-
ized medicine and treatments. Because distinct cytokine secretion
patterns are associated with distinct differentiation lineages, secre-
tomic proﬁling may aid in understanding of CSC differentiation
and tumor evolution.
One of the major challenges in designing effective personal-
ized cancer therapeutics and early diagnosis has been the lack of
adequate technologies to comprehensively characterize inter- and
intra-tumor heterogeneity in the clinical settings. Single-cell anal-
ysis of cytokine proﬁles are possible correlates to evaluate whether
there is a high degree of intra-tumor heterogeneity of cancer phe-
notypes, and provide valuable insights into the origins of tumor
heterogeneity, the mechanisms of the complex signaling networks
that mediate the characteristics of individual tumor cells, and
the extent of tumor differentiation and evolution, that has the
potential to enable the development of more effective personalized
medicines for human cancers.
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